215 related articles for article (PubMed ID: 32923973)
1. Tumour vessel remodelling: new opportunities in cancer treatment.
Ganss R
Vasc Biol; 2020; 2(1):R35-R43. PubMed ID: 32923973
[TBL] [Abstract][Full Text] [Related]
2. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation.
Liang Q; Zhou L; Li Y; Liu J; Liu Y
J Drug Target; 2022 Feb; 30(2):119-130. PubMed ID: 33960252
[TBL] [Abstract][Full Text] [Related]
3. The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.
Ileiwat ZE; Tabish TA; Zinovkin DA; Yuzugulen J; Arghiani N; Pranjol MZI
Front Immunol; 2022; 13():976677. PubMed ID: 36045675
[TBL] [Abstract][Full Text] [Related]
4. Improved Immunotherapy Efficacy by Vascular Modulation.
Newport EL; Pedrosa AR; Njegic A; Hodivala-Dilke KM; Muñoz-Félix JM
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680355
[TBL] [Abstract][Full Text] [Related]
5. In-silico dynamic analysis of cytotoxic drug administration to solid tumours: Effect of binding affinity and vessel permeability.
Vavourakis V; Stylianopoulos T; Wijeratne PA
PLoS Comput Biol; 2018 Oct; 14(10):e1006460. PubMed ID: 30296260
[TBL] [Abstract][Full Text] [Related]
6. Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy.
Cai Y; Zhang J; Li Z
Biomed Eng Online; 2016 Dec; 15(Suppl 2):155. PubMed ID: 28155728
[TBL] [Abstract][Full Text] [Related]
7. The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking.
Zhao Y; Ting KK; Coleman P; Qi Y; Chen J; Vadas M; Gamble J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917287
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
[TBL] [Abstract][Full Text] [Related]
9. Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion.
Cai Y; Xu S; Wu J; Long Q
J Theor Biol; 2011 Jun; 279(1):90-101. PubMed ID: 21392511
[TBL] [Abstract][Full Text] [Related]
10. Vascular normalization in Rgs5-deficient tumours promotes immune destruction.
Hamzah J; Jugold M; Kiessling F; Rigby P; Manzur M; Marti HH; Rabie T; Kaden S; Gröne HJ; Hämmerling GJ; Arnold B; Ganss R
Nature; 2008 May; 453(7193):410-4. PubMed ID: 18418378
[TBL] [Abstract][Full Text] [Related]
11. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.
Ansardamavandi A; Nikfarjam M; He H
Cells; 2023 Nov; 12(23):. PubMed ID: 38067120
[TBL] [Abstract][Full Text] [Related]
12. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
13. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
Schiffmann LM; Brunold M; Liwschitz M; Goede V; Loges S; Wroblewski M; Quaas A; Alakus H; Stippel D; Bruns CJ; Hallek M; Kashkar H; Hacker UT; Coutelle O
Br J Cancer; 2017 Feb; 116(5):600-608. PubMed ID: 28141797
[TBL] [Abstract][Full Text] [Related]
14. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
16. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake.
Matuszewska K; Pereira M; Petrik D; Lawler J; Petrik J
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503254
[TBL] [Abstract][Full Text] [Related]
17. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
18. Are tumours angiogenesis-dependent?
Verheul HM; Voest EE; Schlingemann RO
J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
[TBL] [Abstract][Full Text] [Related]
19. [Vascular perfusion as the origin of neoplasm resistance to radio- and chemotherapy].
Martinive P; Coucke PA
Rev Med Liege; 2010 Mar; 65(3):133-9. PubMed ID: 20411817
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the tumor vasculature and oxygenation to improve therapy.
Siemann DW; Horsman MR
Pharmacol Ther; 2015 Sep; 153():107-24. PubMed ID: 26073310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
